Premium
Isoxazole derivatives of silatrane: synthesis, characterization, in silico ADME profile, prediction of potential pharmacological activity and evaluation of antimicrobial action
Author(s) -
Adamovich Sergey N.,
Kondrashov Evgeniy V.,
Ushakov Igor A.,
Shatokhiina S.,
Oborina Elizaveta N.,
Vashchenko Alexander V.,
Belovezhets Lydmila A.,
Rozentsveig Igor B.,
Verpoort Francis
Publication year - 2020
Publication title -
applied organometallic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.53
H-Index - 71
eISSN - 1099-0739
pISSN - 0268-2605
DOI - 10.1002/aoc.5976
Subject(s) - chemistry , adme , isoxazole , bacillus subtilis , antimicrobial , stereochemistry , lipinski's rule of five , in silico , proton nmr , combinatorial chemistry , organic chemistry , biochemistry , in vitro , bacteria , gene , biology , genetics
A new family of mono‐ ( 3a‐h ) and bis‐ ( 4a‐g ) isoxazole‐bridged silatranes has been synthesized by the reaction of 3‐aminopropylsilatrane ( 1 ) and 3‐substituted 5‐chloro‐methylisoxazoles ( 2a‐h ). The structure of the isoxazole‐silatrane hybrids is characterized by elemental analysis, FT‐IR, UV, NMR ( 1 H, 13 C, 29 Si and 15 N) spectroscopy, high‐resolution mass spectrometry, and X‐ray diffraction analysis. The in silico ADME (absorption, distribution, metabolism, excretion) assessment reveals that properties of mono‐adducts ( 3a‐h ) are similar to those of drugs obeyed to the Lipinski's rule. The calculated screening of potential pharmacological activity profiles ( in silico PASS program) of isoxazole‐silatranes shows that all synthesized compounds (both mono‐ and bis‐substituted) may have high antitumor action, unlike starting isoxazoles. The preliminary screening of the synthesized silatranes for antimicrobial activity against Enterococcus durans , Bacillus subtilis , Escherichia coli , and Pseudomonas aeruginosa indicates that all test samples are active only against gram‐positive microorganisms. Silatrane 3f displays minimal inhibitory concentration (MIC 12.5 and 6.2 μg ml −1 ) against E. durans and B. subtilis as compared with standard drug gentamicin (MIC 25 and 50 μg ml −1 ).